Structures by: Goud R. N.
Total: 13
C16H16ClN5O6S
C16H16ClN5O6S
Journal of Pharmaceutical Sciences (2012) 101, 664-680
a=7.909(4)Å b=9.467(5)Å c=12.484(7)Å
α=100.151(8)° β=95.950(8)° γ=97.644(9)°
C20H18ClN6O7S
C20H18ClN6O7S
Journal of Pharmaceutical Sciences (2012) 101, 664-680
a=7.512(2)Å b=9.462(3)Å c=17.198(5)Å
α=95.387(5)° β=102.271(5)° γ=110.101(5)°
C21H20O6
C21H20O6
Chem.Commun. (2011) 47, 5013
a=12.5676(11)Å b=7.0425(6)Å c=19.9582(18)Å
α=90.00° β=94.9870(10)° γ=90.00°
C21H20O6
C21H20O6
Chem.Commun. (2011) 47, 5013
a=12.536(3)Å b=7.9916(17)Å c=34.462(7)Å
α=90.00° β=90.00° γ=90.00°
C21H20O6
C21H20O6
Chem.Commun. (2011) 47, 5013
a=35.417(3)Å b=7.7792(7)Å c=12.6482(11)Å
α=90.00° β=90.00° γ=90.00°
Sulfacetamide4-aminopyridineSalt
C8H10N2O3S,C5H6N2
CrystEngComm (2014) 16, 26 5859
a=7.7413(7)Å b=17.8726(16)Å c=11.0065(10)Å
α=90.00° β=97.8790(10)° γ=90.00°
Sulfacetamide4,4'bipyridinecocrystal
C8H10N2O3S,C5H4N1
CrystEngComm (2014) 16, 26 5859
a=11.6469(9)Å b=10.4670(6)Å c=12.4421(9)Å
α=90.00° β=116.510(10)° γ=90.00°
SulfacetamideIsonicotinamidecocrystal
C8H10N2O3S,C6H6N2O,C6H6N2O
CrystEngComm (2014) 16, 26 5859
a=10.7667(4)Å b=9.7508(4)Å c=21.1014(7)Å
α=90.00° β=96.176(3)° γ=90.00°
SulfacetamideCaffeinecocrystal
C8H10N2O3S,C8H10N4O2
CrystEngComm (2014) 16, 26 5859
a=7.1821(6)Å b=30.430(3)Å c=8.8188(7)Å
α=90.00° β=107.6790(10)° γ=90.00°
SulfacetamideTheophyllinecocrystal
C8H10N2O3S,C7H8N4O2
CrystEngComm (2014) 16, 26 5859
a=8.6640(7)Å b=14.9675(13)Å c=15.3632(15)Å
α=110.234(2)° β=106.3650(10)° γ=97.2830(10)°
Furosemide sodium salt trihydrate
C12H10ClN2O5SNa.3H2O
CrystEngComm (2014) 16, 22 4842
a=20.9184(10)Å b=10.4771(6)Å c=7.8468(4)Å
α=90.00° β=95.790(4)° γ=90.00°
2-Bromo-3-hydroxy-6-methylpyridine
C6H6BrNO
Acta Crystallographica Section E (2013) 69, 12 o1729
a=11.4484(19)Å b=9.0914(15)Å c=13.230(2)Å
α=90.00° β=90.00° γ=90.00°
Furosemide potassuium salt monohydrate
C12H10ClN2O5SK.H2O
CrystEngComm (2014) 16, 22 4842
a=18.8967(10)Å b=11.1734(6)Å c=7.3056(4)Å
α=90.00° β=91.346(5)° γ=90.00°